1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

22 Mar 2024
Admin
News Article

Senhwa Biosciences Begins Phase II Study of Silmitasertib

Senhwa Biosciences Starts Phase II Study of Silmitasertib for Community-Acquired Pneumonia with Viral Infection in Taiwan

Overview

Senhwa Biosciences, Inc. (TPEx: 6492), a pharmaceutical company specializing in novel therapeutics for oncology, rare diseases, and infectious diseases, has announced a significant milestone today. The company has successfully administered the first dose to a patient in the phase II trial of Silmitasertib (CX-4945) for treating community-acquired pneumonia (CAP) associated with viral infection in Taiwan. This trial aims to assess whether early intervention with Silmitasertib can halt the progression of CAP by targeting the heightened release of cytokines linked with SARS-CoV-2 and Influenza viruses.

Contributing Hospitals

Leading this phase II trial is an esteemed inter-hospital team specializing in infectious diseases, comprising five reputable hospitals, including National Taiwan University Hospital, National Taiwan University Cancer Center, Far Eastern Memorial Hospital, Tri-Service General Hospital, and Taoyuan General Hospital, Ministry of Health and Welfare.

Recent WHO Warning

The recent warning issued by the World Health Organization (WHO) regarding the potential resurgence of a pandemic, dubbed Disease X, underscores the urgency of developing effective treatments. This threat may arise from the evolution of influenza strains, novel coronaviruses, or entirely new pathogens. Notably, the WHO's risk assessment following the first human case of avian flu and subsequent fatality in mainland China earlier this year has heightened concerns.

Silmitasertib Trial

Silmitasertib (CX-4945), developed by Senhwa Biosciences, offers a promising solution with its unique mechanism targeting human host cells, thereby reducing susceptibility to viral mutations.
The objective of this trial is to provide early medical intervention using Silmitasertib to prevent CAP progression, minimize hospitalizations, improve clinical outcomes, and mitigate risks associated with cytokine release during infections by emerging coronaviruses or influenza viruses.
Other molecule- Furthermore, Senhwa Biosciences is advancing CX-8184, a next-generation drug exhibiting superior antiviral activity and enhanced neutralizing capabilities against viruses.
This drug is being developed for direct administration to the lungs, aiming to offer a convenient and broad-spectrum antiviral treatment option upon successful completion of trials.

About Silmitasertib

Silmitasertib is a groundbreaking small molecule drug that targets the CK2 protein, acting as a CK2 inhibitor.
Clinical studies have demonstrated its safety and tolerability in humans, with easy oral administration.
Silmitasertib is currently undergoing development across several oncology programs for both adults and children with recurrent/advanced or metastatic cancer.
Notably, it has received Orphan Drug Designation from the US FDA for the treatment of Cholangiocarcinoma, Rare Pediatric Disease Designation, and Orphan Drug Designation for Medulloblastoma.
Fast Track Designation was granted for the treatment of recurrent Sonic Hedgehog-driven Medulloblastoma.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!